Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance - Barron's
1. Eli Lilly's Q4 earnings surpassed expectations at $5.32 per share. 2. 2025 guidance predicts adjusted earnings of $22.50 to $24, exceeding estimates. 3. Mounjaro and Zepbound sales reached $3.5 billion and $1.9 billion, respectively. 4. Despite Q4 success, stock gains have lagged behind the S&P 500. 5. Concerns over drug demand could impact investor sentiments going forward.